Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 40 entries
Sorted by: Best Match Show Resources per page
Effects of metformin on tumor hypoxia and radiotherapy efficacy: a [.

EJNMMI research

De Bruycker S, Vangestel C, Staelens S, Wyffels L, Detrez J, Verschuuren M, De Vos WH, Pauwels P, Van den Wyngaert T, Stroobants S.
PMID: 31375940
EJNMMI Res. 2019 Aug 02;9(1):74. doi: 10.1186/s13550-019-0543-4.

BACKGROUND: In a colorectal cancer xenograft model, we investigated the therapeutic effect of metformin on tumor hypoxia with [METHODS: Colo205-bearing mice (n = 40) underwent a baseline [RESULTS: [CONCLUSIONS: Metformin decreased [

Cite
De Bruycker S, Vangestel C, Staelens S, et al. Effects of metformin on tumor hypoxia and radiotherapy efficacy: a [. EJNMMI Res. 2019;9(1):74doi: 10.1186/s13550-019-0543-4.
De Bruycker, S., Vangestel, C., Staelens, S., Wyffels, L., Detrez, J., Verschuuren, M., De Vos, W. H., Pauwels, P., Van den Wyngaert, T., & Stroobants, S. (2019). Effects of metformin on tumor hypoxia and radiotherapy efficacy: a [. EJNMMI research, 9(1), 74. https://doi.org/10.1186/s13550-019-0543-4
De Bruycker, Sven, et al. "Effects of metformin on tumor hypoxia and radiotherapy efficacy: a [." EJNMMI research vol. 9,1 (2019): 74. doi: https://doi.org/10.1186/s13550-019-0543-4
De Bruycker S, Vangestel C, Staelens S, Wyffels L, Detrez J, Verschuuren M, De Vos WH, Pauwels P, Van den Wyngaert T, Stroobants S. Effects of metformin on tumor hypoxia and radiotherapy efficacy: a [. EJNMMI Res. 2019 Aug 02;9(1):74. doi: 10.1186/s13550-019-0543-4. PMID: 31375940; PMCID: PMC6677842.
Copy Download .nbib Format: NLM
Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise.

Diagnostics (Basel, Switzerland)

De Schepper S, Gnanasegaran G, Dickson JC, Van den Wyngaert T.
PMID: 34943570
Diagnostics (Basel). 2021 Dec 11;11(12). doi: 10.3390/diagnostics11122333.

The application of absolute quantification in SPECT/CT has seen increased interest in the context of radionuclide therapies where patient-specific dosimetry is a requirement within the European Union (EU) legislation. However, the translation of this technique to diagnostic nuclear medicine...

Cite
De Schepper S, Gnanasegaran G, Dickson JC, et al. Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise. Diagnostics (Basel). 2021;11(12)doi: 10.3390/diagnostics11122333.
De Schepper, S., Gnanasegaran, G., Dickson, J. C., & Van den Wyngaert, T. (2021). Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise. Diagnostics (Basel, Switzerland), 11(12), . https://doi.org/10.3390/diagnostics11122333
De Schepper, Stijn, et al. "Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise." Diagnostics (Basel, Switzerland) vol. 11,12 (2021). doi: https://doi.org/10.3390/diagnostics11122333
De Schepper S, Gnanasegaran G, Dickson JC, Van den Wyngaert T. Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise. Diagnostics (Basel). 2021 Dec 11;11(12). doi: 10.3390/diagnostics11122333. PMID: 34943570.
Copy Download .nbib Format: NLM
The EANM guideline for radiosynoviorthesis.

European journal of nuclear medicine and molecular imaging

Kampen WU, Boddenberg-Pätzold B, Fischer M, Gabriel M, Klett R, Konijnenberg M, Kresnik E, Lellouche H, Paycha F, Terslev L, Turkmen C, van der Zant F, Antunovic L, Panagiotidis E, Gnanasegaran G, Kuwert T, Van den Wyngaert T.
PMID: 34671820
Eur J Nucl Med Mol Imaging. 2021 Oct 20; doi: 10.1007/s00259-021-05541-7. Epub 2021 Oct 20.

PURPOSE: Radiosynoviorthesis (RSO) using the intraarticular application of beta-particle emitting radiocolloids has for decades been used for the local treatment of inflammatory joint diseases. The injected radiopharmaceuticals are phagocytized by the superficial macrophages of the synovial membrane, resulting in...

Cite
Kampen WU, Boddenberg-Pätzold B, Fischer M, et al. The EANM guideline for radiosynoviorthesis. Eur J Nucl Med Mol Imaging. 2021;doi: 10.1007/s00259-021-05541-7.
Kampen, W. U., Boddenberg-Pätzold, B., Fischer, M., Gabriel, M., Klett, R., Konijnenberg, M., Kresnik, E., Lellouche, H., Paycha, F., Terslev, L., Turkmen, C., van der Zant, F., Antunovic, L., Panagiotidis, E., Gnanasegaran, G., Kuwert, T., Van den Wyngaert, T. (2021). The EANM guideline for radiosynoviorthesis. European journal of nuclear medicine and molecular imaging, . https://doi.org/10.1007/s00259-021-05541-7
Kampen, W U, et al. "The EANM guideline for radiosynoviorthesis." European journal of nuclear medicine and molecular imaging vol. (2021). doi: https://doi.org/10.1007/s00259-021-05541-7
Kampen WU, Boddenberg-Pätzold B, Fischer M, Gabriel M, Klett R, Konijnenberg M, Kresnik E, Lellouche H, Paycha F, Terslev L, Turkmen C, van der Zant F, Antunovic L, Panagiotidis E, Gnanasegaran G, Kuwert T, Van den Wyngaert T. The EANM guideline for radiosynoviorthesis. Eur J Nucl Med Mol Imaging. 2021 Oct 20; doi: 10.1007/s00259-021-05541-7. Epub 2021 Oct 20. PMID: 34671820.
Copy Download .nbib Format: NLM
Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise.

Diagnostics (Basel, Switzerland)

De Schepper S, Gnanasegaran G, Dickson JC, Van den Wyngaert T.
PMID: 34943570
Diagnostics (Basel). 2021 Dec 11;11(12). doi: 10.3390/diagnostics11122333.

The application of absolute quantification in SPECT/CT has seen increased interest in the context of radionuclide therapies where patient-specific dosimetry is a requirement within the European Union (EU) legislation. However, the translation of this technique to diagnostic nuclear medicine...

Cite
De Schepper S, Gnanasegaran G, Dickson JC, et al. Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise. Diagnostics (Basel). 2021;11(12)doi: 10.3390/diagnostics11122333.
De Schepper, S., Gnanasegaran, G., Dickson, J. C., & Van den Wyngaert, T. (2021). Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise. Diagnostics (Basel, Switzerland), 11(12), . https://doi.org/10.3390/diagnostics11122333
De Schepper, Stijn, et al. "Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise." Diagnostics (Basel, Switzerland) vol. 11,12 (2021). doi: https://doi.org/10.3390/diagnostics11122333
De Schepper S, Gnanasegaran G, Dickson JC, Van den Wyngaert T. Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise. Diagnostics (Basel). 2021 Dec 11;11(12). doi: 10.3390/diagnostics11122333. PMID: 34943570; PMCID: PMC8700635.
Copy Download .nbib Format: NLM
Taxonomic revision of the genus .

Fungal systematics and evolution

Seto K, Van den Wyngaert S, Degawa Y, Kagami M.
PMID: 32467913
Fungal Syst Evol. 2020 Jun;5:17-38. doi: 10.3114/fuse.2020.05.02. Epub 2019 Aug 21.

During the last decade, the classification system of chytrids has dramatically changed based on zoospore ultrastructure and molecular phylogeny. In contrast to well-studied saprotrophic chytrids, most parasitic chytrids have thus far been only morphologically described by light microscopy, hence...

Cite
Seto K, Van den Wyngaert S, Degawa Y, et al. Taxonomic revision of the genus . Fungal Syst Evol. 2019;5:17-38doi: 10.3114/fuse.2020.05.02.
Seto, K., Van den Wyngaert, S., Degawa, Y., & Kagami, M. (2020). Taxonomic revision of the genus . Fungal systematics and evolution, 517-38. https://doi.org/10.3114/fuse.2020.05.02
Seto, K, et al. "Taxonomic revision of the genus ." Fungal systematics and evolution vol. 5 (2020): 17-38. doi: https://doi.org/10.3114/fuse.2020.05.02
Seto K, Van den Wyngaert S, Degawa Y, Kagami M. Taxonomic revision of the genus . Fungal Syst Evol. 2020 Jun;5:17-38. doi: 10.3114/fuse.2020.05.02. Epub 2019 Aug 21. PMID: 32467913; PMCID: PMC7250019.
Copy Download .nbib Format: NLM
Effect of sodium administration on fluid balance and sodium balance in health and the perioperative setting. Extended summary with additional insights from the MIHMoSA and TOPMAST studies.

Journal of critical care

Van Regenmortel N, Langer T, De Weerdt T, Roelant E, Malbrain M, Van den Wyngaert T, Jorens P.
PMID: 34798374
J Crit Care. 2022 Feb;67:157-165. doi: 10.1016/j.jcrc.2021.10.022. Epub 2021 Nov 17.

PURPOSE: We aimed to provide an extended analysis of the physiological handling of of the sodium burden induced by maintenance fluids.MATERIALS AND METHODS: We revisited two studies that demonstrated, in healthy volunteers and in surgical patients, that maintenance fluids...

Cite
Van Regenmortel N, Langer T, De Weerdt T, et al. Effect of sodium administration on fluid balance and sodium balance in health and the perioperative setting. Extended summary with additional insights from the MIHMoSA and TOPMAST studies. J Crit Care. 2021;67:157-165doi: 10.1016/j.jcrc.2021.10.022.
Van Regenmortel, N., Langer, T., De Weerdt, T., Roelant, E., Malbrain, M., Van den Wyngaert, T., & Jorens, P. (2022). Effect of sodium administration on fluid balance and sodium balance in health and the perioperative setting. Extended summary with additional insights from the MIHMoSA and TOPMAST studies. Journal of critical care, 67157-165. https://doi.org/10.1016/j.jcrc.2021.10.022
Van Regenmortel, Niels, et al. "Effect of sodium administration on fluid balance and sodium balance in health and the perioperative setting. Extended summary with additional insights from the MIHMoSA and TOPMAST studies." Journal of critical care vol. 67 (2022): 157-165. doi: https://doi.org/10.1016/j.jcrc.2021.10.022
Van Regenmortel N, Langer T, De Weerdt T, Roelant E, Malbrain M, Van den Wyngaert T, Jorens P. Effect of sodium administration on fluid balance and sodium balance in health and the perioperative setting. Extended summary with additional insights from the MIHMoSA and TOPMAST studies. J Crit Care. 2022 Feb;67:157-165. doi: 10.1016/j.jcrc.2021.10.022. Epub 2021 Nov 17. PMID: 34798374.
Copy Download .nbib Format: NLM
Resolution of bortezomib-associated chalazia/blepharitis after switch to ixazomib: A case report.

Current research in translational medicine

Lemoine J, Bonnin A, Marjanovic Z, van de Wyngaert Z, Ikhlef S, Alsuliman T, M'Hammedi-Bouzina F, Mohty M, Malard F.
PMID: 33639586
Curr Res Transl Med. 2021 May;69(2):103283. doi: 10.1016/j.retram.2021.103283. Epub 2021 Feb 24.

No abstract available.

Cite
Lemoine J, Bonnin A, Marjanovic Z, et al. Resolution of bortezomib-associated chalazia/blepharitis after switch to ixazomib: A case report. Curr Res Transl Med. 2021;69(2):103283doi: 10.1016/j.retram.2021.103283.
Lemoine, J., Bonnin, A., Marjanovic, Z., van de Wyngaert, Z., Ikhlef, S., Alsuliman, T., M'Hammedi-Bouzina, F., Mohty, M., & Malard, F. (2021). Resolution of bortezomib-associated chalazia/blepharitis after switch to ixazomib: A case report. Current research in translational medicine, 69(2), 103283. https://doi.org/10.1016/j.retram.2021.103283
Lemoine, Jean, et al. "Resolution of bortezomib-associated chalazia/blepharitis after switch to ixazomib: A case report." Current research in translational medicine vol. 69,2 (2021): 103283. doi: https://doi.org/10.1016/j.retram.2021.103283
Lemoine J, Bonnin A, Marjanovic Z, van de Wyngaert Z, Ikhlef S, Alsuliman T, M'Hammedi-Bouzina F, Mohty M, Malard F. Resolution of bortezomib-associated chalazia/blepharitis after switch to ixazomib: A case report. Curr Res Transl Med. 2021 May;69(2):103283. doi: 10.1016/j.retram.2021.103283. Epub 2021 Feb 24. PMID: 33639586.
Copy Download .nbib Format: NLM
If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment?.

European journal of obstetrics, gynecology, and reproductive biology

Tjalma WAA, van Heerden J, Van den Wyngaert T.
PMID: 34979365
Eur J Obstet Gynecol Reprod Biol. 2021 Nov 11;269:98-101. doi: 10.1016/j.ejogrb.2021.11.008. Epub 2021 Nov 11.

Since the introduction of human papilloma virus (HPV) vaccination, the number of precancerous lesions has decreased in countries with a high HPV vaccination coverage. Currently women who present with a precancerous cervical lesions (CIN2 + ), are often not...

Cite
Tjalma WAA, van Heerden J, Van den Wyngaert T. If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment?. Eur J Obstet Gynecol Reprod Biol. 2021;269:98-101doi: 10.1016/j.ejogrb.2021.11.008.
Tjalma, W. A. A., van Heerden, J., & Van den Wyngaert, T. (2021). If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment?. European journal of obstetrics, gynecology, and reproductive biology, 26998-101. https://doi.org/10.1016/j.ejogrb.2021.11.008
Tjalma, Wiebren A A, et al. "If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment?." European journal of obstetrics, gynecology, and reproductive biology vol. 269 (2021): 98-101. doi: https://doi.org/10.1016/j.ejogrb.2021.11.008
Tjalma WAA, van Heerden J, Van den Wyngaert T. If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment?. Eur J Obstet Gynecol Reprod Biol. 2021 Nov 11;269:98-101. doi: 10.1016/j.ejogrb.2021.11.008. Epub 2021 Nov 11. PMID: 34979365.
Copy Download .nbib Format: NLM
Deregulation and Targeting of TP53 Pathway in Multiple Myeloma.

Frontiers in oncology

Jovanović KK, Escure G, Demonchy J, Willaume A, Van de Wyngaert Z, Farhat M, Chauvet P, Facon T, Quesnel B, Manier S.
PMID: 30687640
Front Oncol. 2019 Jan 09;8:665. doi: 10.3389/fonc.2018.00665. eCollection 2018.

Multiple Myeloma (MM) is an incurable disease characterized by a clonal evolution across the course of the diseases and multiple lines of treatment. Among genomic drivers of the disease, alterations of the tumor suppressor

Cite
Jovanović KK, Escure G, Demonchy J, et al. Deregulation and Targeting of TP53 Pathway in Multiple Myeloma. Front Oncol. 2019;8:665doi: 10.3389/fonc.2018.00665.
Jovanović, K. K., Escure, G., Demonchy, J., Willaume, A., Van de Wyngaert, Z., Farhat, M., Chauvet, P., Facon, T., Quesnel, B., & Manier, S. (2018). Deregulation and Targeting of TP53 Pathway in Multiple Myeloma. Frontiers in oncology, 8665. https://doi.org/10.3389/fonc.2018.00665
Jovanović, Katarina K, et al. "Deregulation and Targeting of TP53 Pathway in Multiple Myeloma." Frontiers in oncology vol. 8 (2018): 665. doi: https://doi.org/10.3389/fonc.2018.00665
Jovanović KK, Escure G, Demonchy J, Willaume A, Van de Wyngaert Z, Farhat M, Chauvet P, Facon T, Quesnel B, Manier S. Deregulation and Targeting of TP53 Pathway in Multiple Myeloma. Front Oncol. 2019 Jan 09;8:665. doi: 10.3389/fonc.2018.00665. eCollection 2018. PMID: 30687640; PMCID: PMC6333636.
Copy Download .nbib Format: NLM
Topical honey application to reduce radiation-induced oral mucositis: a therapy too sweet to ignore?.

The journal of evidence-based dental practice

Van den Wyngaert T.
PMID: 23177499
J Evid Based Dent Pract. 2012 Dec;12(4):203-5. doi: 10.1016/j.jebdp.2012.09.011.

No abstract available.

Cite
Van den Wyngaert T. Topical honey application to reduce radiation-induced oral mucositis: a therapy too sweet to ignore?. J Evid Based Dent Pract. 2012;12(4):203-5doi: 10.1016/j.jebdp.2012.09.011.
Van den Wyngaert, T. (2012). Topical honey application to reduce radiation-induced oral mucositis: a therapy too sweet to ignore?. The journal of evidence-based dental practice, 12(4), 203-5. https://doi.org/10.1016/j.jebdp.2012.09.011
Van den Wyngaert, Tim. "Topical honey application to reduce radiation-induced oral mucositis: a therapy too sweet to ignore?." The journal of evidence-based dental practice vol. 12,4 (2012): 203-5. doi: https://doi.org/10.1016/j.jebdp.2012.09.011
Van den Wyngaert T. Topical honey application to reduce radiation-induced oral mucositis: a therapy too sweet to ignore?. J Evid Based Dent Pract. 2012 Dec;12(4):203-5. doi: 10.1016/j.jebdp.2012.09.011. PMID: 23177499.
Copy Download .nbib Format: NLM
Quality Assessment in FDG-PET/CT Imaging of Head-and-Neck Cancer: One Home Run Is Better Than Two Doubles.

Frontiers in oncology

Van den Wyngaert T, De Schepper S, Carp L.
PMID: 32923399
Front Oncol. 2020 Aug 14;10:1458. doi: 10.3389/fonc.2020.01458. eCollection 2020.

2-deoxy-2-[

Cite
Van den Wyngaert T, De Schepper S, Carp L. Quality Assessment in FDG-PET/CT Imaging of Head-and-Neck Cancer: One Home Run Is Better Than Two Doubles. Front Oncol. 2020;10:1458doi: 10.3389/fonc.2020.01458.
Van den Wyngaert, T., De Schepper, S., & Carp, L. (2020). Quality Assessment in FDG-PET/CT Imaging of Head-and-Neck Cancer: One Home Run Is Better Than Two Doubles. Frontiers in oncology, 101458. https://doi.org/10.3389/fonc.2020.01458
Van den Wyngaert, Tim, et al. "Quality Assessment in FDG-PET/CT Imaging of Head-and-Neck Cancer: One Home Run Is Better Than Two Doubles." Frontiers in oncology vol. 10 (2020): 1458. doi: https://doi.org/10.3389/fonc.2020.01458
Van den Wyngaert T, De Schepper S, Carp L. Quality Assessment in FDG-PET/CT Imaging of Head-and-Neck Cancer: One Home Run Is Better Than Two Doubles. Front Oncol. 2020 Aug 14;10:1458. doi: 10.3389/fonc.2020.01458. eCollection 2020. PMID: 32923399; PMCID: PMC7457015.
Copy Download .nbib Format: NLM
Correction: MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells.

Bioscience reports

Beke L, Kig C, Linders JTM, Boens S, Boeckx A, van Heerde E, Parade M, De Bondt A, Van den Wyngaert I, Bashir T, Ogata S, Meerpoel L, Van Eynde A, Johnson CN, Beullens M, Brehmer D, Bollen M.
PMID: 30504271
Biosci Rep. 2018 Nov 30;38(6). doi: 10.1042/BSR-20150194_COR. Print 2018 Dec 21.

No abstract available.

Cite
Beke L, Kig C, Linders JTM, et al. Correction: MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells. Biosci Rep. 2018;38(6)doi: 10.1042/BSR-20150194_COR.
Beke, L., Kig, C., Linders, J. T. M., Boens, S., Boeckx, A., van Heerde, E., Parade, M., De Bondt, A., Van den Wyngaert, I., Bashir, T., Ogata, S., Meerpoel, L., Van Eynde, A., Johnson, C. N., Beullens, M., Brehmer, D., & Bollen, M. (2018). Correction: MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells. Bioscience reports, 38(6), . https://doi.org/10.1042/BSR-20150194_COR
Beke, Lijs, et al. "Correction: MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells." Bioscience reports vol. 38,6 (2018). doi: https://doi.org/10.1042/BSR-20150194_COR
Beke L, Kig C, Linders JTM, Boens S, Boeckx A, van Heerde E, Parade M, De Bondt A, Van den Wyngaert I, Bashir T, Ogata S, Meerpoel L, Van Eynde A, Johnson CN, Beullens M, Brehmer D, Bollen M. Correction: MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells. Biosci Rep. 2018 Nov 30;38(6). doi: 10.1042/BSR-20150194_COR. Print 2018 Dec 21. PMID: 30504271; PMCID: PMC6278382.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 40 entries